Yousif Capital Management LLC Sells 698 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Yousif Capital Management LLC reduced its holdings in Medpace Holdings, Inc. by 7.8% in Q2, leaving them with 8,205 shares valued at approximately $2.58 million.
• Insider trades indicated that VP Susan E. Burwig and Director Cornelius P. McCarthy III both sold significant shares, cumulatively worth around $5.57 million, representing decreases in their positions.
• Wall Street analysts have varied outlooks on Medpace, with current ratings showing two “Buy”, twelve “Hold”, and three “Sell” recommendations, and an average price target of $430.60.

Yousif Capital Management LLC cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 7.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,205 shares of the company's stock after selling 698 shares during the quarter. Yousif Capital Management LLC's holdings in Medpace were worth $2,575,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in MEDP. GAMMA Investing LLC raised its holdings in Medpace by 37.1% in the 1st quarter. GAMMA Investing LLC now owns 307 shares of the company's stock worth $94,000 after purchasing an additional 83 shares in the last quarter. Blue Trust Inc. raised its holdings in Medpace by 60.5% in the 1st quarter. Blue Trust Inc. now owns 467 shares of the company's stock worth $142,000 after purchasing an additional 176 shares in the last quarter. Cabot Wealth Management Inc. raised its holdings in Medpace by 8.9% in the 1st quarter. Cabot Wealth Management Inc. now owns 17,969 shares of the company's stock worth $5,475,000 after purchasing an additional 1,473 shares in the last quarter. Ausbil Investment Management Ltd bought a new position in Medpace in the 1st quarter worth $601,000. Finally, Sheets Smith Wealth Management raised its holdings in Medpace by 4.6% in the 1st quarter. Sheets Smith Wealth Management now owns 3,289 shares of the company's stock worth $1,002,000 after purchasing an additional 144 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Activity at Medpace

In related news, VP Susan E. Burwig sold 10,000 shares of the stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the sale, the vice president directly owned 57,500 shares of the company's stock, valued at approximately $27,600,000. This represents a 14.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of the stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $465.04, for a total transaction of $772,896.48. Following the sale, the director directly owned 10,197 shares in the company, valued at $4,742,012.88. This trade represents a 14.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 161,266 shares of company stock worth $74,111,427 in the last ninety days. 20.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Zacks Research lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a report on Monday, September 22nd. Rothschild & Co Redburn downgraded shares of Medpace from a "buy" rating to a "neutral" rating and upped their target price for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Deutsche Bank Aktiengesellschaft upped their target price on shares of Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Finally, TD Cowen reaffirmed a "sell" rating and issued a $366.00 target price (up from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Medpace presently has an average rating of "Reduce" and an average price target of $430.60.

Medpace Price Performance

NASDAQ:MEDP opened at $528.07 on Friday. The firm's 50-day moving average price is $492.23 and its 200-day moving average price is $381.83. The company has a market capitalization of $14.83 billion, a PE ratio of 39.26, a P/E/G ratio of 3.27 and a beta of 1.40. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $547.15.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same period in the prior year, the firm posted $2.75 EPS. Medpace's revenue for the quarter was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.